Annals of Surgical Oncology

, Volume 2, Issue 6, pp 488–494 | Cite as

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study

  • John S. Macdonald
  • Thomas R. Fleming
  • Robert F. Peterson
  • Jeffrey L. Berenberg
  • Suzanne McClure
  • Robert A. Chapman
  • Harman J. Eyre
  • Dilip Solanki
  • Anatolio B. CruzJr
  • Robert Gagliano
  • Norman C. Estes
  • Catherine M. Tangen
  • Saul Rivkin
Original Articles


Purpose: To evaluate FAM [5-FU (5-fluorouracil), doxorubicin, mitomycin C] chemotherapy as adjuvant therapy for patients with resected TNM stage I, II, or III gastric carcinoma.

Patients and Methods: One hundred ninety-three eligible patients were accrued from 1978 to 1991 in a phase III trial comparing six cycles (1 year) of postoperative FAM chemotherapy with observation only.

Results: The median follow-up on this study was 9.5 years. For all patients, no differences (log-rank analysis) in disease-free survival (p=0.45) and overall survival (p=0.57) between FAM therapy (93 cases) and surgery (100 cases) were observed. Quality of surgical resection affected survival irrespective of FAM use. Cases with curative resection, defined in a retrospective review of pathology and surgical reports as cases having no evidence of residual disease in the abdomen and tumor-free margins >1 cm, had superior survival compared to cases not meeting these requirements (p<0.001). FAM was well tolerated with 6% (five of 90) of cases demonstrating grade IV hematologic toxicity. There were two drug-related fatalities (one cardiomyopathy, one hematolytic uremic syndrome).

Conclusion: FAM is not effective adjuvant therapy for TNM stage I, II, and III patients with resected gastric cancer. Future adjuvant studies must emphasize prospective surgical quality control to assure enrollment of appropriately staged and resected cases and wide participation to assure adequate case accrual over a reasonable period.

Key Words

Gastric cancer Adjuvant chemotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boring CC, Squires TS, Tong T. Cancer statistics 1993.CA Cancer J Clin 1993;43:7–25.PubMedGoogle Scholar
  2. 2.
    Vezerides MP, Wanebo HJ. Gastric cancer: surgical approach. In: Ahlgren JD, Macdonald JS, eds.Gastrointestinal oncology. Philadelphia, PA: Lippincott, 1992:159–70.Google Scholar
  3. 3.
    Dupont B Jr, Lee JR, Burton GR, et al. Adenocarcinoma of the stomach: review of 1497 cases.Cancer 1978;41:941–7.PubMedGoogle Scholar
  4. 4.
    Coombes RC, Schein PS, Chilvers C, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer.J Clin Oncol 1990;8:1362–1269.PubMedGoogle Scholar
  5. 5.
    Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer.Cancer 1982;49:1116–22.Google Scholar
  6. 6.
    Schein PS. Gastric cancer: approaches to adjuvant therapy. In: Ahlgren JD, Macdonald JS, eds.Gastrointestinal oncology. Philadelphia, PA: Lippincott, 1992:189–93.Google Scholar
  7. 7.
    Macdonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.Ann Intern Med 1980;93:533–6.PubMedGoogle Scholar
  8. 8.
    American Joint Committee for Cancer Staging and End Results Reporting.Manual for staging of cancer. Chicago, 1978:75–6.Google Scholar
  9. 9.
    SAS Institute Inc.SAS/STAT User's Guide. Version 6 edition. Cary, NC: SAS Institute, 1990.Google Scholar
  10. 10.
    Kaplan EL, Meier P. Nonparametric estimation from complete incomplete observations.J Am Stat Assoc 1958;53:457–81.Google Scholar
  11. 11.
    Cox DR. Regression models and life-tables.J R Stat Soc [Br] 1972;34:187–220.Google Scholar
  12. 12.
    Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach.Cancer 1969;24:223–9.PubMedGoogle Scholar
  13. 13.
    Longmire WP, Kuzma JW, Dixon WJ. The use of triethylenethiophosphoramide as an adjuvant to the treatment of gastric carcinoma.Ann Surg 1968;167:293–300.PubMedGoogle Scholar
  14. 14.
    Higgins AG, Amadeo JH, Smith DE, et al. Efficacy of prolonged intermittent therapy with combined 5-FU-methyl-CCNU following resection for gastric carcinoma.Cancer 1983;52:1105–12.PubMedGoogle Scholar
  15. 15.
    Engstrom PJ, Lavin PT, Douglass HO Jr, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients: Eastern Cooperative Oncology Group Study (EST 3275).Cancer 1985;55:1868–76.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc 1995

Authors and Affiliations

  • John S. Macdonald
    • 1
  • Thomas R. Fleming
    • 2
  • Robert F. Peterson
    • 3
  • Jeffrey L. Berenberg
    • 4
  • Suzanne McClure
    • 5
  • Robert A. Chapman
    • 6
  • Harman J. Eyre
    • 7
  • Dilip Solanki
    • 8
  • Anatolio B. CruzJr
    • 9
  • Robert Gagliano
    • 10
  • Norman C. Estes
    • 11
  • Catherine M. Tangen
    • 2
  • Saul Rivkin
    • 12
  1. 1.Comprehensive Cancer CenterTemple UniversityPhiladelphiaUSA
  2. 2.Southwest Oncology Group Statistical CenterSeattleUSA
  3. 3.Scott & White Clinic/Texas A&MTempleUSA
  4. 4.Cancer Center of HawaiiHonoluluUSA
  5. 5.University of Texas Medical Branch-GalvestonGalvestonUSA
  6. 6.Henry Ford HospitalDetroitUSA
  7. 7.University of Utah Medical CenterSalt Lake CityUSA
  8. 8.University of Oklahoma Health Science CenterOklahoma CityUSA
  9. 9.University of Texas Health Science Center at San AntonioSan AntonioUSA
  10. 10.Humana Hospital SunriseLas VegasUSA
  11. 11.University of Kansas Medical CenterKansas CityUSA
  12. 12.Puget Sound Oncology ConsortiumSeattleUSA

Personalised recommendations